Freeport-McMoRan Inc. (0R2O)
London Exchange · UK · prices in USD · close of 23 Oct 2026
Key indicators
| Last close | USD 64.60 |
|---|---|
| 52-week range | 38.34 – 80.89 |
| Return, 1 month / 3 months | −10.9% / +4.0% |
| Return, 1 year / 3 years | +55.4% / +99.1% |
| Trend | Below its 200-day average |
| RSI (14) | 34 |
| Volatility (1 year) | 49.1% |
| Worst drawdown (1 year) | -23.5% |
| Average daily value traded | 2.22M USD |
| Dividend yield | 0.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Freeport-McMoRan Inc. is a mining company based in Phoenix, Arizona, in the United States. It explores for, develops and produces copper, gold and molybdenum, and its operations include large open-pit mines in North and South America and a major copper and gold mining complex in Indonesia. Its customers are industrial users of metals, including smelters, refiners and manufacturers that turn copper into wire, tubing and other products used in construction, electrical equipment and transport.
Freeport-McMoRan Inc. trades under the code 0R2O on the London Exchange in UK, with its price quoted in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Freeport-McMoRan Inc. (0R2O) trades on the London Exchange in UK. It last closed at USD 64.60 on 23 October 2026.
Its price-based Market X-Ray is 56 out of 100 (a fair price profile), ranking 1,681 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 55.4% and over the last three months it rose 4.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 60 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -0.4% | ||
| From 52-week high | -18.0% | ||
| Momentum | 71 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 4.1% | ||
| 6-month return | 0.7% | ||
| 12-month return, skipping the last month | 74.4% | ||
| Stability (higher is calmer) | 46 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 49.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -23.5% | ||
| Liquidity | 61 · Fair | Moderate trading activity. | |
| Average daily value traded | 2.22M USD | ||
| Zero-volume days | 1.7% | ||
| Income | 23 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.5% | ||
| Years with dividends | 5 |
Strengths
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | −9.5% |
|---|---|
| 1 month | −10.9% |
| 3 months | +4.0% |
| 6 months | +0.7% |
| 1 year | +55.4% |
| 3 years | +99.1% |
| 5 years | +81.1% |
Signals
| 50-day / 200-day average | 71.72 / 64.84 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.73 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 Oct 2026 | USD 0.0750 |
| 14 Jul 2026 | USD 0.0750 |
| 14 Apr 2026 | USD 0.0750 |
| 14 Jan 2026 | USD 0.0750 |
| 14 Oct 2025 | USD 0.0750 |
| 14 Jul 2025 | USD 0.0750 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.